Bronchogen Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Bronchogen?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Bronchial epithelial regeneration, COPD models, pulmonary fibrosis, DNA stabilization, epigenetic gene regulation
• First Characterized: 1990s, Saint Petersburg Institute of Bioregulation and Gerontology
• Molecular Weight: 446.45 g/mol
• Research Status: Preclinical only; no human clinical trials published
• Key Mechanisms: Direct DNA binding and stabilization, chromatin remodeling, lung-specific transcription factor activation
• Published Studies: Approximately 10-15 peer-reviewed publications, predominantly from a single Russian research group
• Clinical Trial Status: No registered human clinical trials identified
• Regulatory Classification: Research use only; not approved for human therapeutic use in any major jurisdiction

What is Bronchogen?

Bronchogen is a synthetic tetrapeptide with the amino acid sequence Alanine-Glutamic Acid-Aspartic Acid-Leucine, abbreviated AEDL from its single-letter amino acid codes. It belongs to a class of compounds called peptide bioregulators: short synthetic peptides modeled on sequences found in specific organ tissues and proposed to exert regulatory effects on those tissues.

The peptide emerged from a decades-long Soviet and Russian research program based at the Saint Petersburg Institute of Bioregulation and Gerontology. Beginning in the 1970s under military medical research funding, scientists at this institute extracted short peptides from animal organ tissues and tested whether these fragments retained tissue-specific biological activity when administered to other animals. Bronchogen was characterized specifically from bronchial tissue studies and assigned to lung and airway research applications.

The lead researcher associated with this program, Professor Vladimir Khavinson (1946-2024), published over 775 scientific works and held 196 patents covering peptide bioregulators across multiple organ systems. The program he directed produced a family of organ-targeted tetrapeptides, each assigned to a specific tissue: Bronchogen for bronchial and pulmonary tissue, Epithalon for the pineal gland, Vesugen for vascular tissue, and others. Khavinson passed away in January 2024, leaving a complex scientific legacy that includes genuinely novel observations about short peptides and DNA interaction alongside questions about independent reproducibility.

What distinguishes Bronchogen from most research peptides is its proposed mechanism. Rather than binding to a cell surface receptor and triggering an intracellular signaling cascade, Bronchogen is investigated for its ability to cross cell membranes, enter the nucleus, and interact directly with DNA. Two acidic residues in its sequence (glutamic acid and aspartic acid) create a negative charge at physiological pH that researchers propose enables specific electrostatic interactions with DNA bases. This makes it a candidate for epigenetic research rather than conventional receptor pharmacology.

Nearly all published research on Bronchogen originates from the Saint Petersburg institute or its direct collaborators. Independent replication by outside research groups has not been published in indexed journals to date, which is a significant limitation discussed in detail in the limitations section of this article.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Bronchogen’s four-amino acid structure is compact enough to cross both cell membranes and nuclear membranes, which is central to its proposed mechanism of action. Most peptides of similar size remain extracellular or are degraded before reaching intracellular targets. Fluorescence-labeling studies have confirmed nuclear localization of AEDL in HeLa cells, demonstrating that the peptide does reach the nucleus in cell culture models [1].

The two acidic residues in the sequence, glutamic acid at position two and aspartic acid at position three, carry negative charges at physiological pH. DNA strands are also negatively charged along their phosphate backbone, yet researchers propose that the specific spatial arrangement of AEDL’s charged residues allows it to interact with DNA base pairs rather than being repelled by the backbone. Biophysical studies characterize the binding as occurring at the major groove of DNA, specifically at guanine N7 positions, through non-covalent hydrogen bonding and van der Waals interactions [1,2].

The peptide does not carry a dedicated PubChem CID, reflecting its status as a specialized research compound outside mainstream pharmaceutical databases. Its small size (446.45 g/mol) and water solubility make it straightforward to handle in laboratory settings, though lyophilized storage at -20 degrees C is recommended to maintain integrity over extended periods.

Mechanisms of Action Being Investigated

Bronchogen research focuses on three interconnected mechanisms: direct DNA stabilization, sequence-specific DNA binding linked to epigenetic regulation, and downstream modulation of lung-specific gene expression. These mechanisms differ fundamentally from receptor-mediated pathways common to most research peptides.

DNA Thermostabilization

The most quantitatively characterized effect of Bronchogen is its ability to raise the melting temperature of DNA. Differential scanning microcalorimetry experiments using calf thymus and mouse liver DNA preparations showed that Bronchogen increases DNA melting temperature by approximately 3.1 degrees C [3]. This thermal stabilization indicates the peptide strengthens the hydrogen bonding network holding the two DNA strands together.

The stabilization effect occurs within a specific molar ratio range between peptide and DNA, suggesting the peptide occupies saturable binding sites rather than non-specifically aggregating along the helix. Importantly, studies report that Bronchogen does not visibly distort the double helix structure, meaning it stabilizes without introducing conformational damage [3]. Proposed consequences of this stabilization include enhanced resistance to oxidative strand breaks, reduced spontaneous unwinding under cellular stress, and potentially greater genomic stability in rapidly dividing or metabolically stressed cells.

Sequence-Specific Binding and Epigenetic Relevance

Bronchogen does not bind DNA uniformly. Oligonucleotide binding assays and fluorescence studies identify preferential binding to CTG-rich motifs and CNG sequences, where the N position represents any nucleotide [1,4]. CNG sites are cytosine DNA methylation sites, the molecular marks that define the epigenome. Binding at these sites places Bronchogen squarely in epigenetic territory: by interacting preferentially with methylated cytosine positions, the peptide could influence how methylation patterns are read by transcriptional machinery without necessarily altering the underlying DNA sequence [4].

This is a mechanistically plausible but not yet fully characterized pathway. The biophysical evidence for sequence-preferential binding is published, but whether this binding actually modifies methylation patterns, blocks methyl-binding proteins, or alters chromatin accessibility in a biologically meaningful way requires further investigation.

Chromatin Remodeling Through Histone Interaction

Beyond direct DNA binding, Bronchogen has been investigated for interactions with histones, the proteins around which DNA is wrapped. Published studies document binding interactions with linker histone H1 and core histones H2B, H3, and H4, with specific interactions at lysine residues on histone H3 noted [5]. Histone H3 lysine modifications are among the most studied epigenetic marks, governing whether genomic regions adopt tightly packed heterochromatin (gene-silencing) or loosely organized euchromatin (gene-accessible) configurations.

If Bronchogen shifts the balance toward euchromatin at lung-specific gene loci, this would explain the downstream gene expression changes observed in cell culture studies. The chromatin interaction data provide a mechanistic bridge between the peptide’s DNA-binding chemistry and its reported transcriptional effects, though direct visualization of chromatin state changes in response to Bronchogen treatment has not been published.

Lung-Specific Gene Expression Modulation

The most applied mechanistic research on Bronchogen examines which genes change expression in human bronchial epithelial cells following peptide treatment. A 2014 study in the journal Lung documented upregulation of several transcription factors central to pulmonary development and maintenance [5]:

NKX2-1 (also called TTF-1) is the master transcription factor governing lung epithelial cell identity. Its upregulation suggests Bronchogen promotes differentiation toward mature bronchial epithelial phenotypes. FOXA1 and FOXA2, forkhead box transcription factors critical for respiratory tract development, were also activated. SCGB1A1 and SCGB3A2, secretoglobin genes involved in surfactant production and epithelial regeneration, showed increased expression. Hoxa3, a developmental transcription factor, increased 1.4-1.7 fold specifically in bronchial epithelial cells [5].

Expression of MUC4 and MUC5AC (mucin genes), NOS-3 (nitric oxide synthase with vascular and anti-inflammatory roles), and proliferation marker Ki-67 also changed following treatment. The anti-apoptotic protein Mcl-1 showed enhanced expression, suggesting pro-survival signaling in bronchial cells [5].

A notable observation from this research is that gene expression changes were more pronounced in aged cell cultures (passage 14) compared to young cultures (passage 1). This age-differential effect aligns with the broader focus of the Saint Petersburg institute on aging-related tissue decline and positions Bronchogen as potentially more relevant to age-associated lung function changes than to acute injury in young tissue [5,6].

Anti-Inflammatory Activity

Animal model studies in COPD-like conditions document several anti-inflammatory effects. Bronchogen treatment normalized levels of TNF-alpha and IL-6 in airway fluid, reduced neutrophilic infiltration in bronchoalveolar lavage samples, decreased elastase activity, and restored macrophage counts in airways [7,8]. NOS-3 upregulation, noted in the gene expression data, also contributes an anti-inflammatory dimension through nitric oxide-mediated vascular regulation.

These anti-inflammatory findings are internally consistent with the epithelial regeneration data: reducing chronic inflammatory burden in airways creates conditions more favorable for epithelial repair. Whether the anti-inflammatory effects are primary or secondary to epithelial restoration remains unclear.

Major Areas of Research

Bronchogen research concentrates in four main areas, each grounded in a small number of published studies from the originating research group. The body of evidence is narrow by the standards of most compounds reviewed in this library, and each area reviewed here should be understood as preliminary rather than established.

COPD and Obstructive Lung Disease Models

Rat models with COPD induced by nitrogen dioxide exposure provide the primary animal data for Bronchogen. A 2015 study by Kuzubova and colleagues in the Bulletin of Experimental Biology and Medicine represents the most detailed morphological investigation available [7]. Histological examination of bronchial tissue from Bronchogen-treated animals showed elimination of goblet cell hyperplasia, restoration of ciliated epithelial cells, prevention of squamous metaplasia, reduced lymphocytic infiltration, and decreased emphysematous changes after one month of treatment. The treated animals’ bronchial architecture approached that of healthy control animals on histological examination.

A 2017 study by Titova and colleagues confirmed anti-inflammatory effects in the same obstructive lung pathology model, documenting decreased neutrophilic inflammation by cell counting in bronchoalveolar lavage fluid and normalization of cytokine profiles in airway fluids [8].

Key Research Highlights:

• Goblet cell hyperplasia eliminated in nitrogen dioxide-induced rat COPD model
• Ciliated epithelial cell recovery documented histologically after one month
• Neutrophilic inflammation reduced with normalized cytokine profiles in airway fluids

These findings are significant in that they describe structural restoration of bronchial architecture, not merely symptomatic improvement. However, nitrogen dioxide-induced COPD models in rats do not fully replicate the pathology of human COPD, and one-month treatment windows provide no information about long-term durability of effects.

DNA Interaction and Epigenetic Research

The biophysical characterization of Bronchogen’s DNA interactions represents the most technically rigorous segment of the published literature. Three dedicated studies have investigated binding parameters, sequence preferences, and structural consequences of AEDL-DNA interaction [1,2,3,4].

The 2011 calorimetry study establishing the 3.1 degree C melting temperature increase [3] and the fluorescence-labeled peptide nuclear penetration study [1] provide the foundation. The 2017 spectroscopic and calorimetric analysis by Morozova and colleagues added binding affinity measurements, stoichiometry determination, and thermodynamic parameter characterization for the AEDL-DNA interaction [4].

Key Research Highlights:

• DNA melting temperature increased by 3.1 degrees C confirmed by calorimetry
• Nuclear localization of fluorescence-labeled peptide confirmed in HeLa cells
• Preferential binding to CTG-rich motifs and CNG methylation sites characterized

This epigenetic angle is scientifically novel and potentially high-impact if independently replicated. Short peptides that modulate DNA accessibility without covalent modification represent an understudied area of molecular biology with theoretical implications for age-related epigenetic drift.

Pulmonary Fibrosis Research

Bleomycin-induced pulmonary fibrosis models provide an additional preclinical test system for Bronchogen. Referenced in Khavinson and colleagues’ 2014 gene expression study, fibrosis model data indicate reductions in fibrotic changes in lung parenchyma, decreased collagen deposition, and preservation of normal alveolar architecture compared to untreated controls [5].

Pulmonary fibrosis involves progressive replacement of functional lung tissue with collagen-rich scar tissue, and no approved therapy reverses established fibrosis. The mechanistic rationale for Bronchogen’s proposed anti-fibrotic activity connects to its gene expression profile: upregulation of differentiation transcription factors like NKX2-1 and FOXA2 could promote regeneration of functional epithelial cells rather than fibroblast-driven scar tissue.

Key Research Highlights:

• Reduced fibrotic changes in bleomycin-induced pulmonary fibrosis model
• Decreased collagen deposition in affected lung parenchyma
• Preservation of alveolar architecture relative to untreated fibrosis controls

The published data on fibrosis remain limited to referenced observations rather than a dedicated mechanistic study, leaving this area the least developed of the major research domains.

Aging and Cellular Senescence in Airway Tissue

The observation that Bronchogen’s transcriptional effects are stronger in aged cell cultures than in young ones has generated a distinct research thread around age-related lung decline. A 2012 study by Khavinson and colleagues examined whether short peptides stimulate cell differentiation more potently in aging cell populations [6]. Bronchial epithelial cells at late passage (simulating cellular aging) showed greater fold-changes in differentiation factor expression following Bronchogen treatment than early-passage cells.

This age-differential finding is one of the more intriguing observations in the Bronchogen literature. Age-related decline in lung function involves progressive loss of epithelial maintenance capacity, increased oxidative stress, and declining regenerative response. If a peptide’s regulatory effects intensify precisely where regenerative capacity is most compromised, that property would be mechanistically meaningful for age-associated lung disease research.

Key Research Highlights:

• Greater transcription factor upregulation in aged cell cultures (passage 14) than young cultures (passage 1)
• Differentiation-promoting effects more pronounced in senescent bronchial epithelial cells
• Secretory IgA production elevated 2-3 fold in some studies, supporting mucosal immune function

Surfactant Protein B levels were also elevated following treatment, a finding relevant to alveolar stability since Surfactant Protein B is essential for reducing surface tension in the alveolar air-liquid interface.

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Published pharmacokinetic data for Bronchogen is largely absent from the peer-reviewed literature. No formal bioavailability studies using standard ADME (absorption, distribution, metabolism, excretion) methodology have been published for this compound. The available information comes from cell culture studies demonstrating nuclear penetration and animal studies demonstrating biological effects after administration, which confirm activity but do not characterize the pharmacokinetic pathway in detail.

Plasma half-life has not been established in any published source. For a tetrapeptide of 446.45 g/mol, enzymatic degradation by peptidases in blood is expected to be rapid based on general peptide pharmacology, though the specific amino acid sequence and any modification to standard peptide termini could alter this estimate. No published stability data in plasma is available for confirmation.

Distribution and Metabolism

The most relevant distribution data comes from the fluorescence-labeled peptide nuclear penetration study [1], which confirmed that AEDL reaches the cell nucleus in HeLa cell cultures. This demonstrates intracellular and intranuclear distribution at the cellular level, but tissue-level distribution in intact organisms has not been mapped.

Metabolism is expected to follow standard peptide degradation through proteolytic cleavage into individual amino acids, all four of which (alanine, glutamic acid, aspartic acid, leucine) are non-essential amino acids found in normal metabolic pools. No evidence of unusual metabolic products or accumulation has been reported, though this absence of data reflects the overall thinness of pharmacokinetic investigation rather than confirmed safety.

Delivery Methods Under Investigation

• Subcutaneous injection: The predominant delivery route used in published animal studies; assumed to provide systemic distribution
• Intranasal delivery: Theoretically relevant for a pulmonary-targeted peptide but not specifically documented in published studies for this compound
• Oral delivery: Not documented in published Bronchogen literature; small peptides are generally subject to gastrointestinal proteolysis, limiting oral bioavailability without protective formulation

Excretion and Clearance

No published clearance or excretion data exists for Bronchogen. Based on general tetrapeptide pharmacology, degradation products would be expected to enter amino acid recycling pools with renal excretion of any remaining fragments. The absence of formal excretion studies represents a significant gap for any future clinical development pathway.

Research Limitations and Evidence Gaps

Current Research Gaps

Single-Source Publication Problem The most significant limitation in the Bronchogen literature is that nearly all published research originates from one institution: the Saint Petersburg Institute of Bioregulation and Gerontology, or its direct collaborators. Science advances through independent replication by researchers with no stake in the original findings. No independent research group has published confirmatory studies of Bronchogen’s DNA stabilization, gene expression, or tissue regeneration effects in indexed peer-reviewed journals. This does not mean the findings are incorrect, but it means they remain unvalidated by the normal mechanisms of scientific verification.

Human Clinical Data No human clinical trials of any phase have been published or registered for Bronchogen. All efficacy data derives from cell culture models and rat COPD/fibrosis models. Human lung biology, disease pathology, and pharmacokinetics differ substantially from rat models. Conclusions about potential human relevance cannot be drawn from this evidence base.

Mechanistic Completeness While the DNA-binding mechanism has biophysical support, the full causal chain from peptide administration to observed tissue changes has not been reconstructed. It remains unclear whether the gene expression changes in cell culture cause the histological improvements seen in animal models, or whether multiple parallel mechanisms operate. The proposed connection between DNA binding and chromatin remodeling has not been demonstrated through chromatin immunoprecipitation or equivalent techniques specific to Bronchogen treatment.

Pharmacokinetics Absent No plasma half-life, bioavailability, tissue distribution, or clearance data has been published. This is a fundamental gap: without knowing how much peptide reaches target tissues, at what concentration, and for how long, interpreting dose-response relationships and comparing across studies is not possible.

Methodological Considerations Animal COPD models induced by nitrogen dioxide exposure do not replicate the complex multifactorial pathology of human COPD, which involves decades of cigarematic or occupational exposure, genetic susceptibility, and systemic inflammation. One-month treatment windows in rats provide no long-term safety or durability data.

Areas Needing Further Investigation

• Independent replication of DNA stabilization and gene expression findings by research groups outside Saint Petersburg
• Formal human pharmacokinetic studies to establish whether the peptide reaches pulmonary tissue at biologically relevant concentrations after systemic administration
• Long-term safety assessment in animal models extending beyond one month
• Mechanistic studies directly linking DNA binding to chromatin state changes using modern epigenomic techniques
• Human clinical trial data of any phase to establish safety before efficacy can be meaningfully assessed

Regulatory and Research Status

Current Classification

FDA Status Bronchogen is not approved by the FDA for any human therapeutic use. It is not listed as an approved drug, an approved active ingredient in any formulation, or an investigational new drug with registered clinical trials in the ClinicalTrials.gov database. The compound is available for legitimate preclinical laboratory research only.

International Perspective The compound was developed in Russia and some formulated products have been commercially available in Russian and Eastern European markets as dietary supplements under regulatory frameworks that differ from FDA or EMA standards. This commercial availability does not constitute clinical approval under rigorous drug development standards and should not be conflated with established therapeutic status. The European Medicines Agency has not evaluated or approved Bronchogen. No major Western regulatory body has issued formal guidance documents specific to this compound.

WADA Status Bronchogen does not appear on the World Anti-Doping Agency prohibited list as a specifically named compound. However, athletes subject to anti-doping testing should note that WADA’s prohibited list includes peptide hormones, growth factors, related substances, and mimetics as a class, which could encompass peptide bioregulators depending on their mechanism of action and biological effects. Athletes should seek qualified anti-doping counsel before any use.

Research Community Approach

Academic interest in short regulatory peptides and their interactions with DNA has grown independently of the Khavinson program, driven by the broader field of epigenetics. Bronchogen itself has not attracted substantial research activity outside Russia. Researchers interested in this compound face the challenge of working from a limited, single-source literature without established independent replication benchmarks. Institutional review and biosafety compliance are required for any legitimate research use, consistent with standard peptide research protocols.

Future Research Directions

Independent replication of the core findings, particularly the DNA thermal stabilization result and the bronchial epithelial gene expression profile, represents the most critical next step for establishing scientific credibility. If replicated, the DNA-binding mechanism would represent a genuinely novel approach to pulmonary tissue research with potential implications for epigenetic aging research. Formal pharmacokinetic characterization and safety toxicology studies in standard preclinical models would be prerequisites for any rational path toward human trials.

Key Research Findings

DNA Thermal Stabilization Confirmed by Calorimetry

Research Focus: Whether Bronchogen physically stabilizes DNA structure in cell-free conditions Key Results: Bronchogen increased the melting temperature of both calf thymus and mouse liver DNA preparations by 3.1 degrees C as measured by differential scanning microcalorimetry; binding was saturable and occurred within a specific molar ratio range; the double helix structure was not visibly distorted Significance: This is the most technically rigorous finding in the Bronchogen literature, grounded in a direct biophysical measurement technique. It establishes that the peptide genuinely interacts with DNA and measurably alters its thermal properties, providing physical evidence for the proposed DNA stabilization mechanism Limitations: Cell-free system using purified DNA; whether equivalent stabilization occurs within living cells under physiological conditions remains untested [3]

Nuclear Localization of AEDL in Cell Culture

Research Focus: Whether the AEDL tetrapeptide physically enters the cell nucleus Key Results: Fluorescence-labeled AEDL was detected within the nuclei of HeLa cells; the peptide showed preferential binding to oligonucleotides containing CNG sequences; binding was confirmed at the major groove of DNA at guanine N7 positions Significance: Establishes the cellular plausibility of the proposed DNA-binding mechanism by demonstrating actual nuclear localization; without this, the DNA interaction mechanism would be purely theoretical Limitations: HeLa cells are a cancer cell line with atypical membrane and nuclear transport characteristics; nuclear penetration in primary bronchial epithelial cells or intact animal tissue has not been directly visualized [1]

Bronchial Epithelial Gene Expression Profile

Research Focus: Which genes change in human bronchial epithelial cell cultures following Bronchogen treatment Key Results: Upregulation of NKX2-1, FOXA1, FOXA2, SCGB1A1, SCGB3A2; Hoxa3 enhanced 1.4-1.7 fold; enhanced Ki-67 and Mcl-1 expression; mucin gene modulation; effects more pronounced in aged (passage 14) versus young (passage 1) cultures Significance: Identifies a coherent set of lung-specific differentiation and regeneration genes as Bronchogen targets, providing a transcriptional rationale for the tissue regeneration effects observed in animal models Limitations: Cell culture data; no independent replication; the same research group produced the cell culture data and the animal model data, limiting cross-validation [5]

COPD Model Histological Recovery

Research Focus: Structural changes in bronchial epithelium of rats with nitrogen dioxide-induced obstructive lung pathology Key Results: Elimination of goblet cell hyperplasia; restoration of ciliated epithelial cells; prevention of squamous metaplasia; reduced lymphocytic infiltration; reduced emphysematous changes; treated animals’ bronchial architecture approached healthy control morphology after one month Significance: Documents structural, not merely functional, restoration of bronchial architecture in an animal model; the histological endpoint is more objective than symptomatic measurements Limitations: Nitrogen dioxide-induced rat COPD is a limited model of human disease; one-month treatment window; no follow-up data after treatment cessation; single research group [7]

Anti-Inflammatory Effects in Obstructive Lung Model

Research Focus: Inflammatory mediator and immune cell profiles in bronchial lavage fluid from treated rats Key Results: Decreased neutrophilic inflammation by direct cell counting; normalized cytokine profiles including TNF-alpha and IL-6 reduction; decreased elastase activity; restoration of macrophage levels in airways Significance: Complements the histological recovery data by showing that structural improvement correlates with reduced inflammatory burden, providing mechanistic consistency across two independent readouts from the same model Limitations: Same rat model and research group as the histological study; cytokine normalization in animals does not predict equivalent effects in human airway inflammation [7,8]

Age-Differential Transcriptional Response

Research Focus: Whether Bronchogen’s transcriptional effects differ between young and aged bronchial epithelial cell cultures Key Results: Greater fold-changes in differentiation factor expression in passage 14 (aged) cells compared to passage 1 (young) cells; Secretory IgA production elevated 2-3 fold in some studies; Surfactant Protein B levels elevated Significance: If a peptide’s regenerative effects intensify in aging tissue, that property could be mechanistically valuable for age-associated lung conditions. The observation connects the Bronchogen research to the broader epigenetic aging field Limitations: Cell passage number is an imperfect proxy for organismal aging; whether this differential response occurs in vivo in aged animals has not been tested; the observation requires independent replication [5,6]

Frequently Asked Questions

What is Bronchogen used for in research?

Bronchogen is studied as a potential regulator of lung tissue in preclinical research models. Scientists investigate its effects on bronchial epithelial cell regeneration, inflammation in COPD-like animal models, and the expression of genes involved in lung development and maintenance. All research is conducted in cell cultures and animal models; no human clinical applications have been approved or clinically tested.

Is Bronchogen the same as AEDL?

Yes. AEDL is the single-letter amino acid code abbreviation for the peptide sequence Alanine-Glutamic Acid-Aspartic Acid-Leucine, which is the full chemical identity of Bronchogen. The two names refer to the same tetrapeptide compound. Published scientific papers often use AEDL, while the name Bronchogen is more common in commercial and research supplement contexts.

How does Bronchogen differ from other research peptides?

Most research peptides work by binding to a specific cell surface receptor and triggering intracellular signaling through that receptor. Bronchogen is studied for a different mechanism: it is proposed to enter the cell nucleus and interact directly with DNA, stabilizing the double helix and influencing which genes are expressed. This makes it more relevant to epigenetics research than conventional receptor pharmacology, though the mechanism requires further independent validation.

How much human research exists on Bronchogen?

Very little. No published human clinical trials of any phase have been identified for Bronchogen. The entire published research base consists of approximately 10-15 papers, nearly all from one Russian research institution, conducted in cell cultures and rat animal models. This is a substantial limitation, and claims about human effects cannot be supported by current evidence.

Who developed Bronchogen and when?

Bronchogen was developed through the peptide bioregulator research program at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, led by Professor Vladimir Khavinson. The broader program began in the 1970s under Soviet military medical research funding. Bronchogen as a specific tetrapeptide was characterized from the 1990s onward. Professor Khavinson, who held 196 patents and published over 775 scientific works, passed away in January 2024.

References

1. Fedoreyeva, L.I., Kireev, I.I., Khavinson, V.K., & Vanyushin, B.F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11), 1210-1219. PubMed

2. Kasyanenko, N.A., Bakulev, V.M., Petukhov, M.G., Khavinson, V.K., & Sinyakov, A.N. (2001). Interaction of peptide Ala-Glu-Asp-Leu with synthetic oligonucleotides in solution. Biophysics, 46(2), 233-240. PubMed

3. Monaselidze, J.R., Khavinson, V.K., Gorgoshidze, M.Z., Khachidze, D.G., Lomidze, E.M., Jokhadze, T.A., & Lezhava, T.A. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine, 150(3), 375-377. PubMed

4. Morozova, E.A., Lin’kova, N.S., Khavinson, V.K., Soloviev, A.Y., & Kasyanenko, N.A. (2017). In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry, 58(2), 420-424. PubMed

5. Khavinson, V.K., Tendler, S.M., Vanyushin, B.F., Kasyanenko, N.A., Kvetnoy, I.M., Linkova, N.S., Ashapkin, V.V., Polyakova, V.O., Basharina, V.M., & Bernadotte, A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung, 192(5), 781-791. PubMed

6. Khavinson, V.K., Linkova, N.S., Polyakova, V.O., Kheifets, O.V., & Tarnovskaya, S.I. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine, 153(1), 148-151. PubMed

7. Kuzubova, N.A., Titova, O.N., Platonova, I.S., Preobrazhensky, D.V., Freydin, M.B., & Boldina, M.V. (2015). Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bulletin of Experimental Biology and Medicine, 159(5), 685-688. PubMed

8. Titova, O.N., Kuzubova, N.A., Fedorova, T.A., & Platonova, I.S. (2017). Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 103(2), 201-208. PubMed

9. Khavinson, V.K., & Morozov, V.G. (2003). Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters, 24(3-4), 233-240. PubMed

10. Khavinson, V.K., Linkova, N.S., Kvetnoy, I.M., Polyakova, V.O., Kvetnaia, T.V., Rybakina, E.G., Kozina, L.S., & Semchuk, M.N. (2011). Peptide Ala-Glu-Asp-Leu stimulates expression of genes encoding proteins involved in lung morphogenesis. Bulletin of Experimental Biology and Medicine, 151(3), 322-325. PubMed

11. Vanyushin, B.F., Ashapkin, V.V., & Khavinson, V.K. (2013). Peptide regulation of aging and epigenetic mechanisms. Biology Bulletin Reviews, 3(2), 146-157. PubMed

12. Linkova, N.S., Khavinson, V.Kh., Morozova, E.A., & Polyakova, V.O. (2016). Epigenetic mechanisms of peptide regulation of aging. Advances in Gerontology, 29(1), 22-30. PubMed

13. Khavinson, V.K., Tarnovskaya, S.I., Linkova, N.S., Kvetnoy, I.M., Polyakova, V.O., Kvetnaia, T.V., & Rubtsov, M.A. (2013). Short peptides mimic proteins in their ability to stimulate cell-specific gene expression. Bulletin of Experimental Biology and Medicine, 154(3), 400-404. PubMed

14. Rybakina, E.G., Kozina, L.S., Semchuk, M.N., & Khavinson, V.K. (2010). The role of immunological mechanisms in gerontological effects of small peptides. Advances in Gerontology, 23(4), 550-557. PubMed

15. Khavinson, V.K. (2002). Tissue-specific effects of peptide bioregulators. Annals of the New York Academy of Sciences, 959, 594-600. PubMed